Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT04974775
Active, not recruiting Observational

Swecrit Biobank - Blood Samples From Critically Ill Patients and Healthy Controls

NCT04974775 · tracked via the Priya Life Science Sweden tracker
Sponsor
Skane University Hospital
Phase
Observational
Started
2014-06
Last updated
2025-05-29

Condition(s) studied

Critical IllnessCardiac ArrestSepsisInfluenzaCovid19Trauma

Investigational drug(s) / intervention(s)

Blood collectionBlood collection, serial sampling

Blood collection: Sampling on admission to ICU (all patients)

Blood collection, serial sampling: Additional sampling to admission samples in 1. the Cardiac Arrest group after 12 and 48 hours 2. the Covid-19 group on day 2 and 7 while in the ICU 3. the Covid-19 group after 3 and 12 months.

Study summary

Blood samples are collected and stored in a biobank for later analysis of circulating substances in peripheral blood and genetic variations in patients with severe critical illness and risk of death. The aim is to analyze stored samples in order to identify substances that can help predict the outcome of critically ill patients, but also to optimize treatment and possibly prevent serious illness and death in the future.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Critically ill patients admitted to the ICU * 18 years or older * covid19-verified (covid19-cohort) Exclusion Criteria: * The patient or next of kin decline participation

Primary outcome measure(s)

  • Mortality (all) — 6 months
    Primary outcome when functional outcome cannot be assessed.

Trial sites (4)

FacilityCityRegionStatus
Helsingborg Hospital Helsingborg Sweden
Kristianstad Central Hospital Kristianstad Sweden
Skane University Hospital Lund Sweden
Skane University Hospital Malmö Sweden

More Skane University Hospital trials in Sweden

The Swedish BioFINDER - Preclinical AD Study Recruiting
iACT for PTSD and Chronic Pain Recruiting
Effect of HIgh-flow Therapy in Long-term Oxygen Therapy Recruiting
The Swedish BioFINDER 2 Study Recruiting
Selective Defunctioning Stoma in Low Anterior Resection for Rectal Cancer Recruiting

Other trials for the same condition

Biomarkers After Out-of-hospital Cardiac Arrest- a STEPCARE Substudy Active, not recruiting
Establishment of Reference Limits for Blood Lactate Levels in Intensive Care Patients With a Particular Focus on Age and Sex Active, not recruiting
Predictors for Survival and Good Neurological Outcome in E-CPR and Non CPR Treated Patients Recruiting
The Effect of the Covid-19 Pandemic Among Operated Patients Recruiting
The Intensive Care Platform Trial Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04974775 on ClinicalTrials.gov ↗ ← All trials in Sweden